New Report from the Lung Cancer Screening European Expert Summit Makes the Case for Lung Cancer Screening to Enable Early Detection and Life-Saving Surgery

In Europe, lung cancer ranks as the second most common cancer in men, and the third most common in women, and is the leading cause of cancer-related mortality with approximately 376,000 deaths annually.¹  One of the main reasons for this is that lung cancer is often diagnosed at a late stage when treatment options are limited and survival is poor.² If lung cancer is diagnosed at an early stage, up to 90% of people will survive at least 5 years; if it is diagnosed at a late stage, 5-year survival can be less than 10%.³

In July 2025, Johnson & Johnson convened experts on lung cancer screening from across Europe at the Lung Cancer Screening European Expert Summit at the San Camillo Forlanini Hospital in Rome, Italy.

At the meeting lung cancer experts presented evidence that early detection and treatment can significantly reduce mortality from this deadly disease,^4,5,6  and called for expanded and equitable access to Low Dose CT screening programmes for patients at high risk of lung cancer.
 

Read the report here

1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today. Accessed July 25, 2025
2. World Health Organization. Lung Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer. Accessed July 25, 2025
3. Ning J, Ge T, Jiang M, et al. Early diagnosis of lung cancer: which is the optimal choice?. Aging (Albany NY). 2021;13(4):6214-6227. doi:10.18632/aging.202504
4. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873
5. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30(7):1162-1169. doi:10.1093/annonc/mdz117

6. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-513. doi:10.1056/NEJMoa1911793

    

© Johnson & Johnson and its affiliates 2025. M_EM_SRG_ALLS_409270